Lung Therapeutics, Inc. products

Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease characterized by progressive tissue scarring that prevents proper lung function.  LTI-03 operates through a novel mechanism of action (MOA) that is unlike any MOA seen in the therapeutic candidates of today. By targeting healthy epithelial cells, LTI-03 promotes the protection of lung epithelium while inhibiting fibroblast growth and expansion.

A pleural effusion is defined by the build-up of fluid in the pleural cavity, predominantly resulting from pneumonia.  A loculated pleural effusion (LPE) occurs when scar tissue forms in the pleural cavity, trapping the fluid and preventing drainage.  Our lead compound, LTI-01, is a proenzyme, or zymogen, designed to slowly activate in the pleural space and break up the scar tissue. We believe this unique mechanism helps in efficacy, dosing convenience and avoiding the significant bleeding side effects prevalent in off-label use of other plasminogen activators for the treatment of LPE.